Susquehanna International Group
TPTX

Susquehanna International Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Susquehanna International Group’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-128,400
Closed -$9.66M – 14791
2022
Q2 		$9.66M Buy
+128,400
New +$5.71M ﹤0.01% 2245
2022
Q1 		– Sell
-6,700
Closed -$320K – 14465
2021
Q4 		$320K Buy
6,700
+600
+10% +$26.8K ﹤0.01% 10328
2021
Q3 		$405K Buy
6,100
+2,700
+79% +$192K ﹤0.01% 9913
2021
Q2 		$265K Sell
3,400
-500
-13% -$37K ﹤0.01% 11046
2021
Q1 		$369K Sell
3,900
-7,500
-66% -$892K ﹤0.01% 10167
2020
Q4 		$1.39M Buy
11,400
+4,900
+75% +$537K ﹤0.01% 5913
2020
Q3 		$568K Buy
+6,500
New +$453K ﹤0.01% 7410
2020
Q2 		– Sell
-26,700
Closed -$1.19M – 11251
2020
Q1 		$1.19M Buy
+26,700
New +$1.42M ﹤0.01% 4990
2019
Q4 		– Sell
-11,300
Closed -$425K – 10980
2019
Q3 		$425K Buy
+11,300
New +$492K ﹤0.01% 7642

Susquehanna International Group's TPTX Position: Q3 2022 in Review

Susquehanna International Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 31,218 shares — an estimated $2.35M sold.

Susquehanna International Group first reported a position in TPTX in Q4 2019 and held it in 11 quarters. The position peaked at $3.43M in Q4 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Susquehanna International Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Susquehanna International Group sold 31,218 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $2.35M.
  • Susquehanna International Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • Susquehanna International Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.43M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Susquehanna International Group's 13F filing for Q3 2022, filed 14 Nov 2022.